Nektar Therapeutics

Immunology biotech

NKTR · Nasdaq · United States

Share price · NKTR

$34.42-39.22 (-53.26%) 3M

close as of 2026-11-18 · 24h delayed · vol 811K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NKTR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Oct 2026-7.3%
  2. 1 Oct 2026-22.4%
  3. 22 Sep 2026-8.8%
  4. 3 Sep 2026+5.0%
  5. 2 Jul 2026+10.3%

    Nothing announced by NKTR that day or the session before.

  6. 30 Jun 2026+6.8%
  7. 20 Apr 2026+18.3%
  8. 11 Feb 2026+18.5%
  9. 10 Feb 2026+51.1%
  10. 22 Dec 2025-7.2%

Share of unusual movement by asset

For each asset, the share of NKTR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
rezpegaldesleukin
events and moves
2474%
Avipendekin pegol
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—20%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
IL-2 mutein (Treg-selective)Protein / enzyme therapeutic
Atopic DermatitisAlopecia Areata
Preclinical / Unstaged
IL-15 receptorOther
Bladder Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
May 2028 (1)
rezpegaldesleukinPhase 3Moderate-to-Severe Atopic Dermatitis
Est. primary completion 2028-05 · NCT07690371 · CT.gov ↗
What to watch
June 2028 (1)
rezpegaldesleukinPhase 3Moderate-to-Severe Atopic Dermatitis
Est. primary completion 2028-06 · NCT07711418 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 April 2026Topline resultrezpegaldesleukinREZOLVE-AA Phase 2b 52-week extension results of rezpegaldesleukin in alopecia areata
Nektar Therapeutics · Source ↗
10 February 2026Topline resultrezpegaldesleukinPhase 2b REZOLVE-AD of rezpegaldesleukin: 36-week maintenance period results
Nektar Therapeutics · Source ↗
16 December 2025Topline resultrezpegaldesleukinPhase 2b REZOLVE-AA of rezpegaldesleukin narrowly missed its primary endpoint
Nektar Therapeutics · Source ↗
18 September 2025Topline resultrezpegaldesleukinREZOLVE-AD Phase 2b results presented at EADV
24 June 2025Topline resultrezpegaldesleukinPhase 2b REZOLVE-AD of rezpegaldesleukin met its primary endpoint (16-week induction)
Nektar Therapeutics · Source ↗
February 2023Topline resultrezpegaldesleukinPhase 2 lupus study misses its primary endpoint
Nektar Therapeutics · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$9.4M$44M$35M+ $580M short-term inv.$56M-$72M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$10M$39M$39M+ $645M short-term inv.$41M-$76M operating cash flowreport ↗
2026-Q1$11M$36M$732M+ $419M short-term inv.$45M-$44M operating cash flowreport ↗
2025-Q3$12M$27M$41M+ $229M short-term inv.$36M-$49M operating cash flowreport ↗
2025-Q2$11M$30M$43M+ $133M short-term inv.$42M-$46M operating cash flowreport ↗
2025-Q1$10M$30M$39M+ $180M short-term inv.$51M-$49M operating cash flowreport ↗
2024-Q3$24M$35M$30M+ $214M short-term inv.$37M-$44M operating cash flowreport ↗
2024-Q2$23M$30M$28M+ $243M short-term inv.$52M-$38M operating cash flowreport ↗
2024-Q1$22M$27M$49M+ $241M short-term inv.$37M-$48M operating cash flowreport ↗
2023-Q3$24M$24M$65M+ $308M short-term inv.$46M-$42M operating cash flowreport ↗
2023-Q2$21M$30M$51M+ $359M short-term inv.$51M-$52M operating cash flowreport ↗
2023-Q1$22M$30M$77M+ $380M short-term inv.$137M-$52M operating cash flowreport ↗
2022-Q3$24M$34M$106M+ $441M short-term inv.$59M-$83M operating cash flowreport ↗
2022-Q2$22M$43M$78M+ $542M short-term inv.$159M-$75M operating cash flowreport ↗
2022-Q1$25M$107M$68M+ $599M short-term inv.$90M-$88M operating cash flowreport ↗
2021-Q4$25M$100M$25M+ $709M short-term inv.$146M-$152M operating cash flowreport ↗
2021-Q3$25M$104M$54M+ $867M short-term inv.$130M-$101M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$55M$117M$15M+ $231M short-term inv.$41M-$209M operating cash flowreport ↗

Nektar Therapeutics reported full-year 2025 revenue of $55.23M, down 43.9% YoY, with R&D expense of $117.33M, down 3.0% YoY. Cash and equivalents were $15.12M, while cash and investments in marketable securities totaled $245.8M at December 31, 2025, and the company recorded a net loss of $164.08M for the year.

The company highlighted transformative Phase 2b results for rezpegaldesleukin in atopic dermatitis and alopecia areata, with 52-week maintenance data reported in early 2026 and a Phase 3 program in atopic dermatitis expected to start in June 2026. A February 2026 public offering raised $460M in gross proceeds, and a research collaboration with UCSF was established for NKTR-0165 in multiple sclerosis. Upcoming milestones include topline data from the REZOLVE-AA treatment extension in April 2026 and additional readouts through 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$98M$121M$44M+ $211M short-term inv.$30M-$176M operating cash flowreport ↗
2023-FY$90M$114M$35M+ $268M short-term inv.$69M-$193M operating cash flowreport ↗
2022-FY$92M$218M$88M+ $417M short-term inv.$92M-$304M operating cash flowreport ↗
2021-FY$102M$400M$25M+ $709M short-term inv.$131M-$413M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 18 sales ($2.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Zalevsky Jonathan · Chief R&D OfficerOpen-market sale192$35.85$7KForm 4
2026-11-17ROBIN HOWARD W · director, President & CEOOpen-market sale429$35.85$15KForm 4
2026-09-23Ajer Jeffrey Robert · directorAward / grant2,000——Form 4
2026-09-23Brainard Diana · directorAward / grant2,000——Form 4
2026-09-23CHESS ROBERT · directorAward / grant2,000——Form 4
2026-09-23GREER R SCOTT · directorAward / grant2,000——Form 4
2026-09-23WHITFIELD ROY A · directorAward / grant2,000——Form 4
2026-09-23Ajer Jeffrey Robert · directorAward / grant (derivative)4,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 207 reporting institutions held 26.7M shares ($1.9B, 78.0% of shares outstanding).

#InstitutionSharesValue
1FMR LLC4,303,188$309.6M
2BVF INC/IL2,559,595$184.2M
3Two Seas Capital LP1,959,178$141.0M
4VANGUARD CAPITAL MANAGEMENT LLC1,197,055$86.1M
5TWO SIGMA INVESTMENTS, LP930,741$67.0M
6Prosight Management, LP735,000$52.9M
7BlackRock, Inc.692,650$49.8M
8MORGAN STANLEY659,387$47.4M
9ARMISTICE CAPITAL, LLC578,000$41.6M
10Invesco Ltd.567,458$40.8M
11CITADEL ADVISORS LLC513,531$36.9M
12Sofinnova Investments, Inc.509,546$36.7M
13Woodline Partners LP415,335$29.9M
14MILLENNIUM MANAGEMENT LLC404,277$29.1M
15EMERALD ADVISERS, LLC394,604$28.4M